Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Dermatologic 1

Conditions

Waldenstrom Macroglobulinemia 1Uveal Melanoma 1Triple Negative Breast Neoplasms 1Neoplasm Metastasis 1Melanoma 1Lung Neoplasms 1Glioma 1Glioblastoma 1Epstein-Barr Virus Infections 1Cytomegalovirus Infections 1Carcinoma, Non-Small-Cell Lung 1Astrocytoma 1

Interventions

Carboplatin 106Pemetrexed 74Paclitaxel 58Cisplatin 52Erlotinib Hydrochloride 51Radiotherapy 49Docetaxel 43Gemcitabine 41Bevacizumab 41pembrolizumab 30Nivolumab 25Radiosurgery 21Etoposide 20durvalumab 13Cetuximab 13Specimen Handling 12Ipilimumab 12Magnetic Resonance Spectroscopy 11Gefitinib 11Vinorelbine 10Taxes 10Radiation 10Albumin-Bound Paclitaxel 10osimertinib 9Biopsy 9vandetanib 8Topotecan 7Platinum 7Irinotecan 7Drug Therapy 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Lung Neoplasms × Valacyclovir × Clear all
NCT02831933 2023-09-21

ENSIGN

The Methodist Hospital Research Institute

Phase 2 Terminated
11 enrolled 9 charts
DermatologicThoracic

Uveal Melanoma, Lung Neoplasms, Melanoma, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡